January 2022
Issue 1
Letter From the President
The new year has started off not exactly as we had planned. The omicron variant has once again disrupted our clinical and translational science work. As scientists, we can understand the models that predict that cases will start to lower but we also understand the possibility of disability and death that accompany a surge in cases. We are hopeful that our academic and scientific lives can adapt to the current situation, but for many of the communities we work with, the damage can be irreparable. Children, adolescents, young adults, and their families are once again seeing their routines interrupted. People with predisposing conditions to COVID-19 mortality are again worried about their lives.
We are once more asked to think about novel ways that clinical and translational science can serve the needs of our communities. Science has produced treatments, vaccines, and knowledge on how to protect ourselves from COVID-19. But this has not been enough, we still have too many people who are at risk. The way we communicate scientific findings has fallen short. The ACTS community can address this need. As part of our clinical and translational research ideas, we already think about how our findings will be translated to the community. We think about implications for public health measures and public policy. We also need to start thinking about how we communicate this finding to the general population.
If we want to make sure that science can reach everybody, then we need to do a better job of communicating the impact of our findings. This includes improving science education from early ages and evaluating how cognitive bias affects decision making. ACTS has programs in place to address these areas. From inviting high school students to our meeting to including topics on dissemination and science communication in our educational programs. We are certain that we can do better and would welcome recommendations from our members on what resources we can provide to target these issues.
We continue to plan for an in-person Translational Science meeting in Chicago April 20-22, 2022. We are excited to finally meet again and discuss all we have learned from these two years doing clinical and translational science through a pandemic. We also hope to start discussions on how our science will guide us out of the pandemic with new knowledge of what we need to do to address the new challenges faced by the communities we serve.
Karen G. Martinez-Gonzalez, MD, MSc
ACTS President
Translational Science 2022: Early Bird Registration
You won't want to miss this—Translational Science: Transformational Translational Science: Opportunities for Success will return in person April 20-22, 2022 in Chicago, Illinois!
Whether you're looking for insights to kick start your next research project, resources to advance your career, or time to explore new opportunities for collaboration, we've got you covered.
Register by Monday, February 14 to take advantage of early bird pricing.
Journal of Clinical and Translational Science: The Official Journal of ACTS and CR Forum
Share innovative advances in the translational science area to the global research community through JCTS
- Gold Open Access: fully compliant with Open Access Mandates
-
Articles funded by the NIH will be manually sent to PubMed Central
- Articles appear with their final citation details as soon as they are published online
- Prestigious editorial board listing
- Global dissemination of your paper
- Metrics, Altmetrics and Kudos to monitor submissions
Want to receive alerts when new articles are published? Click the 'Add Alert' (🔔) icon here, then login or register for a Cambridge Core account to receive daily, weekly, or monthly updates.
JCTS Featured Article
Check out the article below, ranked in the Association of American Medical Colleges (AAMC) Research on Care Community's Top 10 Articles of 2021!
Christopher J. Lindsel, Gina-Maria Pomann, Robert A. Oster, Sean D. Mooney, and Felicity T. Enders
Published online: 09 March 2021
August M. Watanabe Prize in Translational Research
Indiana University School of Medicine is pleased to award the August M. Watanabe Prize in Translational Research. The prize is one of the nation’s largest and most prestigious awards, recognizing individuals focused on shepherding scientific discoveries into new therapies for patients. The prize is awarded to a senior investigator who has made a significant contribution to the field of translational science. The winner will receive $100,000 and will spend September 14-16, 2022 in Indianapolis, as a vising dignitary, sharing insights and knowledge with audiences at IU School of Medicine and its partner institutions.
Nominees for the August M. Watanabe Prize in Translational Research should be members of the scientific or medical community who have demonstrated outstanding accomplishments in translational research.
The deadline for all nomination materials for the award is January 21, 2022. Any questions about the nomination process may be directed to amwprize@iu.edu or 317-278-2874.
Member Highlights
Do you know someone who deserves to be recognized for outstanding or groundbreaking work? Is your institution embarking on an exciting project? Send ACTS your story to be highlighted in future versions of ACTS Connection.
Submit stories here.
Career Center
The ACTS Career Center is the premier resource for connecting those in the field of translational science with career opportunities. Visit today to find a wealth of resources to help achieve your career goals.
ACTS members receive a 50% discount on the site—use code ACTSMEMBER to save!
Translational Science Today
Faculty Mentor Training Program Strengthens University's ...
Many universities are in search of strategies to improve their faculty diversity and institutional climate. One factor known to be critical for faculty satisfaction is proper mentorship, but many faculty, particularly women and those from...
Read more
health.ucsd.edu